Eli Lilly: Positioned For Robust Q1 As Orforglipron Enhances Long-Term OutlookSeeking Alpha • 04/25/25
Exclusive: US pharma tariffs would raise US drug costs by $51 bln annually, report findsReuters • 04/25/25
LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III StudyZacks Investment Research • 04/21/25
Strength Seen in Lilly (LLY): Can Its 14.3% Jump Turn into More Strength?Zacks Investment Research • 04/21/25
Prediction: Eli Lilly's Newest GLP-1 Drug Will Be a Game-Changer for the StockThe Motley Fool • 04/20/25
Eli Lilly's Experimental Weight Loss Pill Succeeded in Its First Pivotal Trial. Is It Time to Buy?The Motley Fool • 04/19/25
Eli Lilly Vows to Make Weight-Loss Pill in U.S. as Trump Pushes for Domestic ManufacturingBarrons • 04/18/25